About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Combination of Two Groups of Pulmonary Arterial Hypertension Drugs Leads to Enhanced Release of ATP by Human RBCs

by Kathy Jones on September 23, 2013 at 7:19 PM
Font : A-A+

 Combination of Two Groups of Pulmonary Arterial Hypertension Drugs Leads to Enhanced Release of ATP by Human RBCs

A new study published in the journal Experimental Biology and Medicine reports on a finding by researchers at Saint Louis University School of Medicine who discovered that the combination of prostacyclin (PGI2) analogs and phosphodiesterase 5 (PDE5) inhibitors, two groups of drugs used in treating pulmonary arterial hypertension (PAH), leads to higher levels of a potent vasodilator adenosine triphosphate (ATP) being released by human red blood cells (RBCs).

PAH is a chronic disorder characterized by sustained increases in pulmonary vascular resistance leading to pulmonary hypertension and right ventricular heart failure. Although the pathophysiology of PAH is not fully understood, the condition has a poor prognosis in the absence of pharmacological intervention. The major classes of drugs used to treat severe PAH include both PGI2 analogs and PDE5 inhibitors.

Advertisement

It is widely accepted that in vascular smooth muscle cells, PGI2 analogs dilate blood vessels by increasing cyclic adenosine 3',5' mono-phosphate (cAMP) while PDE5 increases cyclic guanosine 3',5' mono-phosphate (cGMP) by inhibiting its breakdown. However, human erythrocytes also express functional prostacyclin receptors (IPRs) and possess PDE5. The binding of PGI2 analogs to the erythrocyte IPR activates a well-defined signaling pathway that stimulates increases in cAMP and culminates in the release of the vasoactive molecule, adenosine 3'5' triphosphate (ATP). When released from circulating erythrocytes in the vascular lumen, ATP binds to receptors on the endothelium of pulmonary vessels resulting in the synthesis of vasodilators. Importantly, the levels of cAMP in the erythrocyte IPR signaling pathway are regulated by PDE3, a PDE that is inhibited by cGMP. Levels of cGMP in erythrocytes are regulated by PDE5.

Dr. Randy Sprague, senior author of this article, said "We hypothesized that increases in cGMP resulting from PDE5 inhibition would prevent the breakdown of IPR-mediated increases in cAMP leading to enhanced ATP release. The major finding of this study is that either of two chemically dissimilar inhibitors of PDE5 augment increases in cAMP and ATP release produced by incubation of erythrocytes with an IPR agonist, UT-15C (treprostinil). Dr. Stephanie Knebel, first author, said "Our results demonstrate a new role for both prostacyclin analogs and PDE5 inhibitors in the regulation of IPR-mediated increases in cAMP and ATP release from human erythrocytes." These findings have implications for the development of new therapeutic approaches to the treatment of conditions such as pulmonary arterial hypertension.
Advertisement

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "This intriguing study by Knebel et al has demonstrated that both PDE5 inhibitors and prostacyclin analogs are involved in the prostacyclin receptor dependent release of cAMP and ATP for human RBCs. Their results suggest new therapeutic approaches for the treatment of pulmonary arterial hypertension".



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
High Blood Pressure Drug Toxicity Diet Lifestyle and Heart Disease Diet and High Blood Pressure Stress and the Gender Divide Silent Killer Diseases Quiz on Hypertension Pulmonary Arterial Hypertension Can Garlic Control High Blood Pressure High Blood Pressure and Herbs 

Recommended Reading
Pulmonary Arterial Hypertension
It can be a serious condition affecting the heart. It is defined as mean pulmonary arterial ......
Pulmonary Embolism and Deep Vein Thrombosis
Deep vein thrombosis (DVT) is a condition where blood clots develop usually in the deep veins of ......
Chronic Obstructive Pulmonary Disease
COPD includes respiratory tract disorders that cause obstruction to airflow. These are chronic .....
Can Garlic Control High Blood Pressure
Want to know how to lower high blood pressure/hypertension? Garlic is a miracle herb that helps to l...
Diet and High Blood Pressure
High blood pressure or hypertension is defined as a blood pressure of above 140 mm Hg (systolic) and...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
High Blood Pressure
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it i...
High Blood Pressure and Herbs
Drug intervention need not be the only option to help lower your moderately high blood pressure. Lif...
Stress and the Gender Divide
Stress has become entwined in the current lifestyle of a young working couple and has resulted in th...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use